T cell immunotherapies are on the cutting-edge of cancer treatments, but a full understanding of how they work has been elusive. In a new study, researchers have revealed key details about the T cell receptor (TCR), which is essential to T cell therapies. The finding has the potential to refine and expand T cell therapies.  

Recently, a research team led by Professor Xie Huiqi at Sichuan University conducted a systematic review of dual-function biomaterials that combine anti-tumor and bone regeneration capabilities for postoperative osteosarcoma treatment. The article categorizes existing research findings into three design strategies: conventional dual-function strategies, enhanced anti-tumor strategies, and temporally regulated strategies. It further explores their design principles, therapeutic efficacy, and potential for clinical translation. This review aims to provide insights for establishing an integrated "anti-tumor and bone regeneration" treatment model and offers perspectives on future research directions in the field. The related work, entitled "Dual-Function Biomaterials for Postoperative Osteosarcoma: Tumor Suppression and Bone Regeneration," has been published in Research.